Zobrazeno 1 - 10
of 383
pro vyhledávání: '"M. Petitou"'
Autor:
E. Fuseau, E. Neuhart, C. Krezel, Pierre Gueret, P. L. M. van Giersbergen, S. Combe, M. Petitou
Publikováno v:
European Journal of Clinical Pharmacology. 72:1041-1050
EP217609 is a parenteral antithrombotic compound combining in one molecule an indirect anti-factor Xa inhibitor, a direct thrombin active site inhibitor and a biotin moiety. The aim of the study is to investigate the safety, pharmacokinetics and phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f98d24b90ff1663cd7cf51659726f709
https://doi.org/10.1007/s00228-016-2077-2
https://doi.org/10.1007/s00228-016-2077-2
Publikováno v:
Journal of Thrombosis and Haemostasis. 12:24-33
Summary Background EP42675 is a first-in-class, synthetic, parenteral, anticoagulant combining in a single molecule a direct thrombin inhibitor and an indirect factor Xa(FXa) inhibitor. Objectives To investigate the safety, pharmacokinetics, and phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::371a93c95035cfe028eba04862e126b6
https://doi.org/10.1111/jth.12453
https://doi.org/10.1111/jth.12453
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
P. Schaeffer, P Savi, F. Bono, Jean-Marc Herbert, M. Petitou, P. Duchaussoy, J P Hérault, L. Millet
Publikováno v:
Journal of Thrombosis and Haemostasis. 6:1697-1706
Summary. Objective: In order to obtain a neutralizable antithrombotic, a chimeric molecule (SSR126517E) containing the sequence of a long-lasting antithrombin (AT)-dependent anti-factor Xa pentasaccharide, idraparinux, linked to a biotin molecule was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::965cc9ebb0253d70fbb026808160d0db
https://doi.org/10.1111/j.1538-7836.2008.03089.x
https://doi.org/10.1111/j.1538-7836.2008.03089.x
Autor:
A Bernat, D.G. Meuleman, C. A. A. Van Boeckel, J.M. Herbert, J. P. Herault, M Petitou, J.C. Lormeau, Peter R. Hoffmann, van Rgm Amsterdam
Publikováno v:
Blood : the Journal of Hematology, 91(11), 4179-4205. American Society of Hematology
SANORG 34006 is a new sulfated pentasaccharide obtained by chemical synthesis. It is an analog of the “synthetic pentasaccharide” (SR 90107/ ORG 31540) which represents the antithrombin (AT) binding site of heparin. SANORG 34006 showed a higher a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a595b9874c2713ce116b1abf796b384b
https://doi.org/10.1182/blood.v91.11.4197
https://doi.org/10.1182/blood.v91.11.4197
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 7:2067-2070
A decasaccharide mimic of the heparan sulfate fragment reported to have high affinity for lipoprotein lipase has been synthesised, and shown to release lipase activity in vivo in the rat.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd3a3f3a2cf174dc54286cc8231b02bd
https://doi.org/10.1016/s0960-894x(97)00361-2
https://doi.org/10.1016/s0960-894x(97)00361-2
Autor:
R. G. M. Van Amsterdam, J.P. He´rault, G.M.T. Vogel, D.G. Meuleman, M. Petitou, J.C. Lormeau, A. Bernat, J.M. Herbert
Publikováno v:
Circulation Research. 79:590-600
SANORG 32701 is a new sulfated pentasaccharide obtained by total chemical synthesis. It is an analogue of the “synthetic pentasaccharide” (SR 90107/ORG 31540), which represents the antithrombin III (AT-III) binding site of heparin. Like SR 90107,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ecbc9071b7c42a66f674a1806028129
https://doi.org/10.1161/01.res.79.3.590
https://doi.org/10.1161/01.res.79.3.590
Autor:
M. Petitou, C. A. A. Van Boeckel
Publikováno v:
ChemInform. 25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d708218e408bf3d8a1736c99f19e5c0
https://doi.org/10.1002/chin.199414305
https://doi.org/10.1002/chin.199414305
Autor:
M. Petitou, C. A. A. Van Boeckel
Publikováno v:
ChemInform. 25
The history of heparin dates back to 1916 when Jay Maclean, a PhD student in Howell’s laboratory, isolated an anticoagulant substance instead of the expected procoagulant phospholipids (1, 2). Since this substance was extracted from liver it was na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebc2955ae7336f3b96be691c9ea34d1f
https://doi.org/10.1002/chin.199443302
https://doi.org/10.1002/chin.199443302